Faeth Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Faeth Therapeutics, Inc. (FTH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 10.13 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-04
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 10.13K shares, a 648.15% increase year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 12.46K shares, a 95.00% decline year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 2.30K shares, a 89.70% decline year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 28.22K shares, a 91.66% decline from fiscal 2024.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 338.42K shares, a 14.49% increase from fiscal 2023.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 295.58K shares, a 93.17% increase from fiscal 2022.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 153.01K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 10.13K shares 10-Q · filed 2026-08-04 | 22.59K shares derived: sum of 3 quarters · filed 2026-08-04 | 24.89K shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 10.13K shares 10-Q · filed 2026-05-15 | 22.59K shares derived: sum of 2 quarters · filed 2026-05-15 | 24.89K shares derived: sum of 3 quarters · filed 2026-05-15 | 37.00K shares derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | 12.46K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 14.76K shares derived: sum of 2 quarters · filed 2026-03-30 | 26.87K shares derived: sum of 3 quarters · filed 2026-03-30 | 28.22K shares 10-K · filed 2026-03-30 |
| 2025-09-30 | 2.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | 14.41K shares derived: sum of 2 quarters · filed 2025-11-14 | 15.76K shares 10-Q · filed 2025-11-14 | 265.08K shares derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-06-30 | 12.11K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 13.46K shares 10-Q · filed 2025-08-05 | 262.78K shares derived: sum of 3 quarters · filed 2025-08-05 | 285.11K shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 1.35K shares 10-Q · filed 2025-05-06 | 250.67K shares derived: sum of 2 quarters · filed 2025-05-06 | 273.00K shares derived: sum of 3 quarters · filed 2025-05-06 | |
| 2024-12-31 | 249.32K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | 271.64K shares derived: sum of 2 quarters · filed 2025-03-28 | 338.42K shares 10-K · filed 2025-03-28 | |
| 2024-09-30 | 22.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 89.10K shares 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | 66.77K shares 10-Q · filed 2024-08-06 | |||
| 2023-12-31 | 81.83K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 196.96K shares derived: sum of 2 quarters · filed 2024-02-29 | 230.60K shares derived: sum of 3 quarters · filed 2024-02-29 | 295.58K shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 115.13K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 148.78K shares derived: sum of 2 quarters · filed 2023-11-07 | 213.75K shares 10-Q · filed 2023-11-07 | 215.80K shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 33.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 98.63K shares 10-Q · filed 2023-08-03 | 100.67K shares derived: sum of 3 quarters · filed 2023-08-03 | 138.28K shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | 64.98K shares 10-Q · filed 2023-05-09 | 67.02K shares derived: sum of 2 quarters · filed 2023-05-09 | 104.63K shares derived: sum of 3 quarters · filed 2023-05-09 | |
| 2022-12-31 | 2.04K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | 39.65K shares derived: sum of 2 quarters · filed 2023-03-29 | 153.01K shares 10-K · filed 2023-03-29 | |
| 2022-09-30 | 37.61K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 150.97K shares 10-Q · filed 2022-11-08 | ||
| 2022-06-30 | 113.36K shares 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |